Am. J. Respir. Crit. Care Med., Volume 161, Number 1, January 2000, 32-35

The Activity of Cytochrome Oxidase Is Increased in Circulating Lymphocytes of Patients with Chronic Obstructive Pulmonary Disease, Asthma, and Chronic Arthritis

JAUME SAULEDA, FRANCISCO JOSÉ GARCÍA-PALMER, GERMAN GONZÁLEZ, ANDREU PALOU, and ALVAR G. N. AGUSTÍ

Servei de Pneumologia and Unidad de Investigación, Hospital Universitari Son Dureta, and Departament de Biologia Fonamental i Ciències de la Salut, Universitat Illes Balears, Palma de Mallorca, Spain

We have previously shown that the activity of cytochrome oxidase (CytOx) in skeletal muscle of patients with chronic obstructive pulmonary disease (COPD) was higher than in healthy control subjects. The mechanisms and implications of this observation were unclear. In particular, it was not known if this abnormality can occur also in: (1) cell types other than muscle cells, and (2) other chronic inflammatory diseases. To obtain further insight into these questions, we measured the activity of CytOx in circulating lymphocytes in patients with stable COPD (n = 17), bronchial asthma (n = 6), or chronic arthritis (n = 5), and in healthy control subjects (n = 8). We found that, compared with healthy subjects (280 ± 117 nKat/µg protein), patients with COPD showed increased CytOx activity (430 ± 150 nKat/µg protein, p = 0.01) in lymphocytes. Further, this activity was negatively related to the degree of airflow obstruction present in these patients (r = 0.53, p < 0.05). We also found that the activity of CytOx in circulating lymphocytes was higher than normal in patients with chronic arthritis (411 ± 130 nKat/µg protein, p < 0.05) and, particularly, in patients with bronchial asthma (1,667 ± 1,027 nKat/µg protein, p < 0.001). These results show that the increased CytOx activity previously reported in skeletal muscle of patients with COPD is also detected in other cell types (such as circulating lymphocytes) and in other chronic inflammatory diseases (such as bronchial asthma and chronic arthritis). The mechanisms and implications of these findings deserve further investigation. Sauleda J, García-Palmer FJ, González G, Palou A, Agustí AGN. The activity of cytochrome oxidase is increased in circulating lymphocytes of patients with chronic obstructive pulmonary disease, asthma, and chronic arthritis.

This article has been cited by other articles:

				J. A. Falk, O. A. Minai, and Z. Mosenifar Inhaled and Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2008; 5(4): 506 - 512. [Abstract] [Full Text] [PDF]

				E Barreiro, A M W J Schols, M I Polkey, J B Galdiz, H R Gosker, E B Swallow, C Coronell, J Gea, and on behalf of the ENIGMA in COPD project Cytokine profile in quadriceps muscles of patients with severe COPD Thorax, February 1, 2008; 63(2): 100 - 107. [Abstract] [Full Text] [PDF]

				L. M. Fabbri, F. Luppi, B. Beghe, and K. F. Rabe Complex chronic comorbidities of COPD Eur. Respir. J., January 1, 2008; 31(1): 204 - 212. [Abstract] [Full Text] [PDF]

				A. G. N. Agusti Systemic Effects of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2005; 2(4): 367 - 370. [Abstract] [Full Text] [PDF]

				C. A. Rouzer, A. T. Jacobs, C. S. Nirodi, P. J. Kingsley, J. D. Morrow, and L. J. Marnett RAW264.7 cells lack prostaglandin-dependent autoregulation of tumor necrosis factor-{alpha} secretion J. Lipid Res., May 1, 2005; 46(5): 1027 - 1037. [Abstract] [Full Text] [PDF]

				E. F. M. Wouters Local and Systemic Inflammation in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2005; 2(1): 26 - 33. [Abstract] [Full Text] [PDF]

				J. S. Dickinson Zimmer, D. F. Dyckes, D. A. Bernlohr, and R. C. Murphy Fatty acid binding proteins stabilize leukotriene A4: competition with arachidonic acid but not other lipoxygenase products J. Lipid Res., November 1, 2004; 45(11): 2138 - 2144. [Abstract] [Full Text] [PDF]

				A.G.N. Agusti, A. Noguera, J. Sauleda, E. Sala, J. Pons, and X. Busquets Systemic effects of chronic obstructive pulmonary disease Eur. Respir. J., February 1, 2003; 21(2): 347 - 360. [Abstract] [Full Text] [PDF]

				E F M Wouters Chronic obstructive pulmonary disease * 5: Systemic effects of COPD Thorax, December 1, 2002; 57(12): 1067 - 1070. [Abstract] [Full Text] [PDF]

				S. V. Culpitt, C. de Matos, R. E. Russell, L. E. Donnelly, D. F. Rogers, and P. J. Barnes Effect of Theophylline on Induced Sputum Inflammatory Indices and Neutrophil Chemotaxis in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., May 15, 2002; 165(10): 1371 - 1376. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1789 - 1804. [Full Text] [PDF]